Vadadustat clinical trials
Also written AKB-6548, MT-6548 and Vafseo.
How each study uses vadadustat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the vadadustat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 27 Mar 2024 · VAFSEO · NDA 215192 (FDA, Drugs@FDA)
- European Union
- 24 Apr 2023 · Vafseo · EMEA/H/C/005131 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
40 studies that test it; most in 2018 (10)
| Year | Studies |
|---|---|
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 5 |
| 2017 | 3 |
| 2018 | 10 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 1 |
| 2024 | 1 |
| 2025 | 4 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 36 · Other 4
Akebia Therapeutics (32) · Tanabe Pharma Corporation (4) · USRC Kidney Research (1) · The University of Texas Health Science Center, Houston (1) · Mackay Memorial Hospital (1) · Paul Potnuru (1)
Often tested with
Tested in the same studies.
Furosemide (1) · Adefovir (1) · Simvastatin (1) · Atorvastatin (1) · Pravastatin (1) · Sulfasalazine (1) · Celecoxib (1)
Studies
Open first, then newest update. How each study uses vadadustat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 40
- Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung InjuryRecruitingPhase 2/3Paul PotnuruNCT07086755Written as Vadadustat 900mg
- Effects of Vadadustat on Anemia, Quality of Life, and Inflammation in Dialysis PatientsNot yet recruitingPhase 4Mackay Memorial HospitalNCT07537816Written as Vadadustat
- To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center HemodialysisCompletedPhase 3Akebia TherapeuticsNCT06901505Written as Vadadustat
- Vafseo Outcomes In-Center ExperienceCompletedPhase 3USRC Kidney ResearchNCT06520826Written as Vadadustat
- Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in JapanCompletedPhase 3Tanabe Pharma CorporationNCT03329196Written as MT-6548
- Efficacy and Safety Study to Evaluate MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in JapanCompletedPhase 3Tanabe Pharma CorporationNCT03402386Written as MT-6548
- Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in JapanCompletedPhase 3Tanabe Pharma CorporationNCT03461146Written as MT-6548
- Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in JapanCompletedPhase 3Tanabe Pharma CorporationNCT03439137Written as MT-6548
- Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating AgentsWithdrawnPhase 3Akebia TherapeuticsNCT05082584Written as Vadadustat
- Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney DiseaseWithdrawnPhase 3Akebia TherapeuticsNCT05082571Written as vadadustat
- Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)CompletedPhase 3Akebia TherapeuticsNCT04313153Written as Vadadustat
- Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)CompletedPhase 2The University of Texas Health Science Center, HoustonNCT04478071Written as vadadustat
- Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis SubjectsCompletedPhase 3Akebia TherapeuticsNCT04707768Written as Vadadustat
- Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin AlfaCompletedPhase 2Akebia TherapeuticsNCT03799627Written as Vadadustat
- 20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and AnemiaCompletedPhase 2Akebia TherapeuticsNCT01906489Written as AKB-6548
- Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)CompletedPhase 3Akebia TherapeuticsNCT02865850Written as Vadadustat
- 42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and AnemiaCompletedPhase 2Akebia TherapeuticsNCT01381094Written as AKB-6548
- Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and AnemiaCompletedPhase 2Akebia TherapeuticsNCT01235936Written as AKB-6548
- 16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic HemodialysisCompletedPhase 2Akebia TherapeuticsNCT02260193Written as AKB-6548
- Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4CompletedPhase 2Akebia TherapeuticsNCT04707573Written as Vadadustat
See all 40 studies that test vadadustat →
Given beside what is tested · 1 — vadadustat is usual care or a partner of the new treatment
Codes
What other systems call vadadustat · ClinicalTrials.gg INT000816
- MeSH (NLM) C000624313vadadustatOne source NLM
- UNII (FDA) I60W9520VVVADADUSTATConfirmed FDA, NLM, Wikidata
- Wikidata Q27280485vadadustatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152811VadadustatOne source FDA
- DrugBank DB12255One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000624313 | vadadustat | One source NLM |
| UNII (FDA) | I60W9520VV | VADADUSTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27280485 | vadadustat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152811 | Vadadustat | One source FDA |
| DrugBank | DB12255 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.